AGL 38.00 Decreased By ▼ -0.31 (-0.81%)
AIRLINK 136.69 Decreased By ▼ -4.71 (-3.33%)
BOP 5.42 Decreased By ▼ -0.22 (-3.9%)
CNERGY 3.83 Decreased By ▼ -0.04 (-1.03%)
DCL 7.59 Increased By ▲ 0.03 (0.4%)
DFML 46.05 Decreased By ▼ -1.35 (-2.85%)
DGKC 80.35 Increased By ▲ 0.60 (0.75%)
FCCL 28.03 Increased By ▲ 0.59 (2.15%)
FFBL 55.21 Increased By ▲ 0.36 (0.66%)
FFL 8.58 Decreased By ▼ -0.02 (-0.23%)
HUBC 112.65 Decreased By ▼ -0.86 (-0.76%)
HUMNL 12.33 Increased By ▲ 1.13 (10.09%)
KEL 3.85 Decreased By ▼ -0.14 (-3.51%)
KOSM 8.07 Decreased By ▼ -0.47 (-5.5%)
MLCF 35.11 Increased By ▲ 0.11 (0.31%)
NBP 66.00 Increased By ▲ 2.20 (3.45%)
OGDC 171.16 Increased By ▲ 1.76 (1.04%)
PAEL 25.18 No Change ▼ 0.00 (0%)
PIBTL 6.20 Increased By ▲ 0.31 (5.26%)
PPL 132.85 Increased By ▲ 7.10 (5.65%)
PRL 24.40 Decreased By ▼ -0.39 (-1.57%)
PTC 14.52 Increased By ▲ 1.26 (9.5%)
SEARL 58.95 Increased By ▲ 1.50 (2.61%)
TELE 7.09 Decreased By ▼ -0.03 (-0.42%)
TOMCL 35.00 No Change ▼ 0.00 (0%)
TPLP 8.09 Increased By ▲ 0.64 (8.59%)
TREET 14.30 Decreased By ▼ -0.02 (-0.14%)
TRG 45.59 Decreased By ▼ -0.95 (-2.04%)
UNITY 25.99 Decreased By ▼ -0.19 (-0.73%)
WTL 1.20 No Change ▼ 0.00 (0%)
BR100 9,084 Decreased By -6.9 (-0.08%)
BR30 27,631 Increased By 252.1 (0.92%)
KSE100 85,453 Decreased By -216.1 (-0.25%)
KSE30 27,149 Decreased By -67.3 (-0.25%)
Business & Finance

AstraZeneca aims for swift approval of COVID-19 vaccine in Brazil

  • President Jair Bolsonaro, a prominent coronavirus skeptic who has said he will not take any COVID-19 vaccine.
  • The Fiocruz biomedical institute, overseen by the federal government, has partnered with AstraZeneca on trials and production of its vaccine.
Published December 30, 2020

SAO PAULO: AstraZeneca said on Wednesday it is working to offer its COVID-19 vaccine to Brazilians as soon as possible, seeking regulatory approval in Brazil after authorization in the UK.

Britain on Wednesday became the first country in the world to approve the coronavirus vaccine developed by Oxford University and AstraZeneca. The U.K. approval offers hope to Brazil, which has made the cheap and sturdy British vaccine the cornerstone of its widely criticized vaccine plan.

President Jair Bolsonaro, a prominent coronavirus skeptic who has said he will not take any COVID-19 vaccine, is under pressure to speed up Brazil's rollout, as regional peers Mexico and Chile have already begun immunizations.

The Fiocruz biomedical institute, overseen by the federal government, has partnered with AstraZeneca on trials and production of its vaccine, with plans to buy 100 million doses for the government by June and eventually produce it locally.

Fiocruz said it will seek approval for the AstraZeneca vaccine on Jan. 15. Health Ministry officials say nationwide vaccinations could begin Jan. 20 in a best-case scenario.

In its statement, AstraZeneca said it would keep up the ongoing submission of its late-stage trial results in order to seek full regulatory approval, but made no mention of seeking emergency use approval: a process that vaccine maker Pfizer Inc has described as cumbersome in Brazil.

The U.K. approval may add to pressure on Brazilian health regulator Anvisa to expedite its own approval processes.

Anvisa did not immediately respond to a request for comment.

While some vaccines, such as Pfizer's COVID-19 shot, must be supercooled to -70 degrees Celsius (-94 Fahrenheit), the AstraZeneca vaccine only needs normal refrigeration, making it a more robust candidate for developing countries such as Brazil.

Comments

Comments are closed.